CA2325345C - Medicaments for inducing cytotoxic t-cells - Google Patents
Medicaments for inducing cytotoxic t-cells Download PDFInfo
- Publication number
- CA2325345C CA2325345C CA2325345A CA2325345A CA2325345C CA 2325345 C CA2325345 C CA 2325345C CA 2325345 A CA2325345 A CA 2325345A CA 2325345 A CA2325345 A CA 2325345A CA 2325345 C CA2325345 C CA 2325345C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- peptide
- compound according
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title claims abstract description 18
- 230000001939 inductive effect Effects 0.000 title abstract description 5
- 150000001413 amino acids Chemical class 0.000 claims abstract description 52
- 229940024606 amino acid Drugs 0.000 claims abstract description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 15
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960000310 isoleucine Drugs 0.000 claims abstract description 14
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000004474 valine Substances 0.000 claims abstract description 14
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 11
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 10
- 229940009098 aspartate Drugs 0.000 claims abstract description 8
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 8
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004473 Threonine Substances 0.000 claims abstract description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 73
- 235000001014 amino acid Nutrition 0.000 claims description 33
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 17
- 241000700605 Viruses Species 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 235000018102 proteins Nutrition 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 208000031886 HIV Infections Diseases 0.000 claims description 8
- 241000700721 Hepatitis B virus Species 0.000 claims description 7
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims description 6
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 6
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 6
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 6
- 229960004748 abacavir Drugs 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 5
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 5
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 4
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229960001627 lamivudine Drugs 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- JTEGQNOMFQHVDC-RQJHMYQMSA-N 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1 JTEGQNOMFQHVDC-RQJHMYQMSA-N 0.000 claims description 3
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 230000001177 retroviral effect Effects 0.000 claims description 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010028921 Lipopeptides Proteins 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 108010067390 Viral Proteins Proteins 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 2
- 229940031348 multivalent vaccine Drugs 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 108010046117 N-palmitoyl-5,6-dipalmitoyl-S-glycerylcysteinyl-seryl-serine Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- XVQKZSLOGHBCET-INVHGPFASA-N tripalmitoyl-S-glyceryl-cysteinyl-seryl-serine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O)CSCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC XVQKZSLOGHBCET-INVHGPFASA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- TVVYVAUGRHNTGT-UGYAYLCHSA-N Asp-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O TVVYVAUGRHNTGT-UGYAYLCHSA-N 0.000 description 10
- SBHUBSDEZQFJHJ-CIUDSAMLSA-N Asp-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O SBHUBSDEZQFJHJ-CIUDSAMLSA-N 0.000 description 10
- AKDOUBMVLRCHBD-SIUGBPQLSA-N Gln-Tyr-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AKDOUBMVLRCHBD-SIUGBPQLSA-N 0.000 description 10
- SJMJMEWQMBJYPR-DZKIICNBSA-N Gln-Tyr-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCC(=O)N)N SJMJMEWQMBJYPR-DZKIICNBSA-N 0.000 description 9
- PFAQXUDMZVMADG-AVGNSLFASA-N Cys-Gln-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PFAQXUDMZVMADG-AVGNSLFASA-N 0.000 description 8
- HVWXAQVMRBKKFE-UGYAYLCHSA-N Ile-Asp-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HVWXAQVMRBKKFE-UGYAYLCHSA-N 0.000 description 8
- FJKXUIJOMUWCDD-FHWLQOOXSA-N Tyr-Gln-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N)O FJKXUIJOMUWCDD-FHWLQOOXSA-N 0.000 description 8
- HZYOWMGWKKRMBZ-BYULHYEWSA-N Val-Asp-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZYOWMGWKKRMBZ-BYULHYEWSA-N 0.000 description 8
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 8
- 108010027338 isoleucylcysteine Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- BBQABUDWDUKJMB-LZXPERKUSA-N Ile-Ile-Ile Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C([O-])=O BBQABUDWDUKJMB-LZXPERKUSA-N 0.000 description 6
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- HJDZMPFEXINXLO-QPHKQPEJSA-N Ile-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N HJDZMPFEXINXLO-QPHKQPEJSA-N 0.000 description 4
- DLEBSGAVWRPTIX-PEDHHIEDSA-N Ile-Val-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)[C@@H](C)CC DLEBSGAVWRPTIX-PEDHHIEDSA-N 0.000 description 4
- KPVLLNDCBYXKNV-CYDGBPFRSA-N Met-Val-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KPVLLNDCBYXKNV-CYDGBPFRSA-N 0.000 description 4
- KIJLSRYAUGGZIN-CFMVVWHZSA-N Tyr-Ile-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O KIJLSRYAUGGZIN-CFMVVWHZSA-N 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- YGDWPQCLFJNMOL-MNXVOIDGSA-N Ile-Leu-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YGDWPQCLFJNMOL-MNXVOIDGSA-N 0.000 description 2
- GAZGFPOZOLEYAJ-YTFOTSKYSA-N Ile-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N GAZGFPOZOLEYAJ-YTFOTSKYSA-N 0.000 description 2
- DSDPLOODKXISDT-XUXIUFHCSA-N Ile-Leu-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O DSDPLOODKXISDT-XUXIUFHCSA-N 0.000 description 2
- AUIYHFRUOOKTGX-UKJIMTQDSA-N Ile-Val-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N AUIYHFRUOOKTGX-UKJIMTQDSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ORWTWZXGDBYVCP-BJDJZHNGSA-N Leu-Ile-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(C)C ORWTWZXGDBYVCP-BJDJZHNGSA-N 0.000 description 2
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 2
- VHTIZYYHIUHMCA-JYJNAYRXSA-N Leu-Tyr-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O VHTIZYYHIUHMCA-JYJNAYRXSA-N 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- ADPHPKGWVDHWML-PPCPHDFISA-N Thr-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N ADPHPKGWVDHWML-PPCPHDFISA-N 0.000 description 2
- XYFISNXATOERFZ-OSUNSFLBSA-N Thr-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N XYFISNXATOERFZ-OSUNSFLBSA-N 0.000 description 2
- SQUMHUZLJDUROQ-YDHLFZDLSA-N Tyr-Val-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O SQUMHUZLJDUROQ-YDHLFZDLSA-N 0.000 description 2
- PYPZMFDMCCWNST-NAKRPEOUSA-N Val-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N PYPZMFDMCCWNST-NAKRPEOUSA-N 0.000 description 2
- BZWUSZGQOILYEU-STECZYCISA-N Val-Ile-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BZWUSZGQOILYEU-STECZYCISA-N 0.000 description 2
- BMOFUVHDBROBSE-DCAQKATOSA-N Val-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N BMOFUVHDBROBSE-DCAQKATOSA-N 0.000 description 2
- 108010081404 acein-2 Proteins 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to compounds containing an amino acid with the sequence X1-Y-X2-D-D-X3 or a nucleic acid coding this amino acid, X1 being at least one chosen amino acid, Y being tyrosine, X2 being an amino acid chosen from the following group: valine, isoleucine and leucine; D being aspartate and X3 being at least one other chosen amino acid, the following amino acids being excluded: TLVLQYVDDLLL and ILVLQYVDDLLL, T being threonine, V being valine, I being isoleucine, L being leucine and Q being glutamine. The invention also relates to medicaments for inducing cytotoxic T-cells, containing this class of compounds.
Description
Medicaments for Inducing C~totoxic T cells The invention relates to a compound or medicament for inducing cytotoxic T cells. The invention further relates to a vaccine against retroviruses such as HIV-1, HIV-2, HTLV-I, HTLV-II as well as against viruses such as hepatitis-B.
It is known from the prior art that by treatment with certain medicaments cytotoxic T cells (CTL) may be induced.
Cytotoxic T cells eliminate inter alia virus infected cells specifically.
In the treatment of HIV infections, inhibitors of viral enzyme reverse transcriptase are employed. One important reverse transcriptase inhibitor used clinically is the medicament 3TC (which is (-)2'-deoxy-3'-thiacytidine or lamivudine). However, HIV may become resistant to this medicament by mutating methionine to isoleucine or valine at codon 194 of reverse transcriptase (PNAS 1993: 90: 5653-6).
The same mutation also leads to resistance to other reverse transcriptase inhibitors such as 1592U89 (abacavir), zalcitabin (DDC), didanosin (DDI), and 2'deoxy-5-fluoro-3'thiacytidine (FTC). Other viruses also have reverse transcriptase or similar DNA polymerases that like HIV
reverse transcriptase contain the sequence YMDD at the active catalytic center. The same mutation of methionine to valine in the YMDD sequence of hepatitis B DNA polymerase also induces resistance in the hepatitis B virus to 3TC, a medicament used to fight the hepatitis B virus.
From the later published application WO 98/23755, the following amino acid sequences are known for the treatment of multiple sclerosis:
TLVLQYVDDLLL and ILVLQYVDDLLL, whereby T = threonine, V =
valine, I - isoleucine, L = leucine, and Q = glutamine.
It is known from the prior art that by treatment with certain medicaments cytotoxic T cells (CTL) may be induced.
Cytotoxic T cells eliminate inter alia virus infected cells specifically.
In the treatment of HIV infections, inhibitors of viral enzyme reverse transcriptase are employed. One important reverse transcriptase inhibitor used clinically is the medicament 3TC (which is (-)2'-deoxy-3'-thiacytidine or lamivudine). However, HIV may become resistant to this medicament by mutating methionine to isoleucine or valine at codon 194 of reverse transcriptase (PNAS 1993: 90: 5653-6).
The same mutation also leads to resistance to other reverse transcriptase inhibitors such as 1592U89 (abacavir), zalcitabin (DDC), didanosin (DDI), and 2'deoxy-5-fluoro-3'thiacytidine (FTC). Other viruses also have reverse transcriptase or similar DNA polymerases that like HIV
reverse transcriptase contain the sequence YMDD at the active catalytic center. The same mutation of methionine to valine in the YMDD sequence of hepatitis B DNA polymerase also induces resistance in the hepatitis B virus to 3TC, a medicament used to fight the hepatitis B virus.
From the later published application WO 98/23755, the following amino acid sequences are known for the treatment of multiple sclerosis:
TLVLQYVDDLLL and ILVLQYVDDLLL, whereby T = threonine, V =
valine, I - isoleucine, L = leucine, and Q = glutamine.
The object of the invention is to make available a medicament that may be used to effectively block or positively affect the course of viral infections, particularly HIV or hepatitis B infections. This medicament should be suitable both for prevention of an infection, e.g. as a preventive vaccine, and for the therapy of an already established infection.
This object is fulfilled by the features of claim 1. Useful embodiments of the invention result from the features of claims 2 through 29.
According to the invention, a compound or medicament is provided for the induction of cytotoxic T cells containing or consisting of an amino acid or the nucleic acid encoding this amino acid, where such amino acid has the following sequence:
X1-Y-X2-D-D-X3, wherein X1 - at least one of any amino acid, Y - tyrosine, X2 - one amino acid selected from the following group: valine, isoleucine, and leucine, D - aspartate, and X3 - at least one additional of any amino acid, with the exception of the following amino acid sequences:
LRVEYLDDR, TLVLQYVDDLLL, and ILVLQYVDDLLL, with T = threonine, V = valine, I - isoleucine, L = leucine, Q = glutamine, and R = arginine;
as well as a method for prevention or treatment of infections with viruses, preferably mutated HIV, HIV-1, HIV-2, HTLV-I, or HTLV-II viruses, or mutated hepatitis-B viruses, or a disease that responds to induction of cytotoxic T cells consisting of administering effective doses of the medicament comprising the amino acid with the following sequence:
This object is fulfilled by the features of claim 1. Useful embodiments of the invention result from the features of claims 2 through 29.
According to the invention, a compound or medicament is provided for the induction of cytotoxic T cells containing or consisting of an amino acid or the nucleic acid encoding this amino acid, where such amino acid has the following sequence:
X1-Y-X2-D-D-X3, wherein X1 - at least one of any amino acid, Y - tyrosine, X2 - one amino acid selected from the following group: valine, isoleucine, and leucine, D - aspartate, and X3 - at least one additional of any amino acid, with the exception of the following amino acid sequences:
LRVEYLDDR, TLVLQYVDDLLL, and ILVLQYVDDLLL, with T = threonine, V = valine, I - isoleucine, L = leucine, Q = glutamine, and R = arginine;
as well as a method for prevention or treatment of infections with viruses, preferably mutated HIV, HIV-1, HIV-2, HTLV-I, or HTLV-II viruses, or mutated hepatitis-B viruses, or a disease that responds to induction of cytotoxic T cells consisting of administering effective doses of the medicament comprising the amino acid with the following sequence:
X1-Y-X2-D-D-X3, wherein X1 = at least one of any amino acid, Y - tyrosine, X2 - one amino acid selected from the following group: valine (V), isoleucine (I), and leucine (L), - aspartate, and X3 - at least one additional of any amino acid, or nucleic acid encoding such amino acid, and/or the use for producing a medicament comprising the following amino acid:
X1-Y-X2-D-D-X3, wherein X1 - at least one of any amino acid, Y - tyrosine, X2 - one amino acid selected from the following group: valine, isoleucine, and leucine, D - aspartate, and X3 - at least one additional of any amino acid, or a nucleic acid encoding such amino acid sequence for production of a medicament for the prevention or treatment of a viral infection, preferably mutated HIV, HIV-l, HIV-2, HTLV-I, HTLV-II, or mutated hepatitis B infection, or a disease which responds to induction of cytotoxic T cells.
The medicament in this invention induces cytotoxic T cells which destroy cells particularly infected with mutated HIV
viruses. Surprisingly, the sequences of this invention form T cell epitopes that are able to bind to HLA-A2 molecules and induce specific T cell receptors against themselves. Thus, it is possible to specifically target HIV mutants that arise in treatment with 3TC and abacavir.
X1-Y-X2-D-D-X3, wherein X1 - at least one of any amino acid, Y - tyrosine, X2 - one amino acid selected from the following group: valine, isoleucine, and leucine, D - aspartate, and X3 - at least one additional of any amino acid, or a nucleic acid encoding such amino acid sequence for production of a medicament for the prevention or treatment of a viral infection, preferably mutated HIV, HIV-l, HIV-2, HTLV-I, HTLV-II, or mutated hepatitis B infection, or a disease which responds to induction of cytotoxic T cells.
The medicament in this invention induces cytotoxic T cells which destroy cells particularly infected with mutated HIV
viruses. Surprisingly, the sequences of this invention form T cell epitopes that are able to bind to HLA-A2 molecules and induce specific T cell receptors against themselves. Thus, it is possible to specifically target HIV mutants that arise in treatment with 3TC and abacavir.
According to one embodiment, the peptide consists of nine amino acids. X1 may consist of a sequence of four or five of any additional amino acids, X3 of one or two additional of any amino acids. Such an amino acid sequence is especially suited to immunize against mutant HIV viruses, but also against other viruses, e.g. mutated hepatitis B viruses.
For purposes of immunization, the amino acid sequence may be a component of a peptide or protein. The peptide or protein may be coupled to a lipopeptide or lipoprotein, preferably tripalmitoyl-S-glyceryl-cysteinyl-Beryl-serine. Depending on the purpose, the peptide or protein may be contained within a liposome or ISCOM (immunostimulatory complex). The peptide or protein may however also be coupled to a viral protein which preferably is selected from the following group: HIV virus-like particles, HIV gag particles, or HBs antigens.
This peptide may preferably be present as a peptide-HLA
complex in soluble form, e.g. as HLA-A2 tetramer. The above-mentioned complex may be bound to a liposome. The peptide may however also be part of a cell presenting an antigen, preferably a dendritic cell, macrophage, B cell, or CD4+ T
cell. This may be achieved both by exogenic addition of the peptide to the cell and endogenic processing of proteins expressed in the cell.
According to the invention, this medicament may further contain cytokines such as interleukin-2 and/or GM-CSF, or polyvalent vaccines. It has proven especially beneficial to select the amino acid sequence from among the following sequences:
IVIYQYVDDL(SEQ ID N0:1), IVICQYVDDL (SEQ ID N0:2), IVIYQYIDDL(SEQ ID N0:3), IVICQYIDDL (SEQ ID N0:4), ITIYQYVDDL(SEQ ID N0:5), ITICQYVDDL (SEQ ID N0:6), ITIYQYIDDL(SEQ ID N0:7), ITICQYIDDL (SEQ ID N0:8), IIIYQYVDDL(SEQ ID N0:9), IIICQYVDDL (SEQ ID NO:10) IIIYQYIDDL(SEQ ID N0:11), IIICQYIDDL (SEQ ID N0:12), MVIYQYVDDL(SEQ ID N0:13), MVICQYVDDL (SEQ ID N0:14), MVIYQYIDDL(SEQ ID N0:15), MVICQYIDDL (SEQ ID N0:16), VIYQYVDDL (SEQ ID N0:17), VICQYVDDL (SEQ ID N0:18), VIYQYIDDL (SEQ ID N0:19), VICQYIDDL (SEQ ID N0:20), LIYQYVDDL (SEQ ID N0:21), LICQYVDDL (SEQ ID N0:22), LIYQYIDDL (SEQ ID N0:23), LICQYIDDL (SEQ ID N0:24), TILQYVDDILL Q ID N0:25), TICQYVDDILL
(SE (SEQ ID
N0:26), ILQYVDDIL (SEQ ID N0:27), ILQYIDDIL (SEQ ID N0:28), TIVQYVDDILL TIVQYIDDILL
(SEQ ID (SEQ ID
N0:29), N0:30), IVQYIDDIL (SEQ ID N0:31), IVQYIDDIL (SEQ ID N0:32), ILVQYVDDIL(SEQ ID N0:33), ILVQYIDDIL (SEQ ID N0:34), IIIQYVDDIL(SEQ ID N0:35), IIIQYIDDIL (SEQ ID N0:36), ILIQYVDDIL(SEQ ID N0:37), ILIQYIDDIL (SEQ ID N0:38), VLYQYVDDL (SEQ ID N0:39), VLCQYVDDL (SEQ ID N0:40), VLYQYIDDL (SEQ ID N0:41), VLCQYIDDL (SEQ ID N0:42), where V = valine, I - isoleucine, L = leucine, M =
methionine, C = cysteine, and Q = glutamine. The nucleic acid sequence may be a DNA or RNA sequence. It is possible for the nucleic acid sequence to be a component of a plasmid or viral vector, preferably of a recombinant vaccinia virus or recombinant adenovirus, or a retroviral vector. The nucleic acid sequence may also be a component of retroviral vectors or attenuated retroviruses. Furthermore, the nucleic acid may be a component of a bacterial vector, preferably a recombinant BCG or salmonella vector or inactivated virus, preferably HIV virus. According to the invention, the medicament may also be used in the ex vivo production of T
cells or T cell receptors.
An additional object of the present invention is the use of a medicament according to the present invention for prevention or treatment of viral infection, preferably involving mutated HIV, HIV-1, HIV-2, HTLV-I, or HTLV-II viruses, or mutated hepatitis B viruses. The viruses may also be mutated viruses resistant to (-)-2',3'-dideoxy-3'-thiacytidine [3TC
(lamivudine)], (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purine-9-yl]-2-cyclopentene-1-methanol [abacavir], 2',3'-dideoxyinosine [didanosin], 2',3'-dideoxycytidine [zalcitabin], (-)-2'-deoxy-5-fluoro-3'-thiacytidine [FTC].
The efficacy of the medicament of this invention is, for example, explained using a graphic representation of experimental results. The following is shown here:
Fig. 1 recognition of CTL epitope VIYQYVDDL (SEQ ID N0:17) or VIYQYIDDL (SEQ ID N0:19) by CTL clone ETMV1 and non-recognition of CTL epitope VIYQYMDDL described above by the same clone, Fig. 2 specific lysis of clone of ETMV1 during titration of peptides VIYQYVDDL (SEQ ID N0:17) and VIYQYIDDL
(SEQ ID N0:19), Fig. 3 recognition of peptide VIYQYVDDL (SEQ ID N0:17), and Fig. 4 non-recognition of peptides VIYQYVDDL (SEQ ID
N0:17) and VIYQYIDDL (SEQ ID N0:19) by CTL clone EB3, which recognizes the wild-type sequence VIYQYMDDL.
In Fig. 1, the peptides were pre-incubated at a concentration of 1 ~Cg/ml for one hour with autologous EBV transformed B-cell lines labelled with 5lchromium. Four hours after addition of clone ETMVl with an effector-target ratio of 15:1, the supernatant was harvested and the specific lysis was calculated based on the amount of chromium released. The p17-peptide KIRLRPGGK was used as control. As can be inferred from Fig. 1, only peptides IVIYQYVDDL (SEQ ID NO:1), VIYQYVDDL (SEQ ID N0:17), and VIYQYIDDL (SEQ ID N0:19) were recognized, which contain resistance mutations against reverse transcriptase inhibitors. Wild-type peptide VIYQYMDDL was not recognized.
In order to achieve the results represented in Fig. 2, the peptides described therein were pre-incubated for one hour at concentrations as indicated with autologous EBV-transformed B-cell lines labelled with 5lchromium. Four hours after addition of clone ETMV1 with an effector-target ratio of 5:1, the supernatant was harvested and the specific lysis was calculated based on amounts of chromium released.
Fig. 3 indicates recognition of peptide VIYQYVDDL (SEQ ID
N0:17) (=RT50 M/V). It is HLA-A2 restricted. The shown results were achieved by pre-incubating the peptide and control peptide for one hour at a concentration of 10 ug/ml with autologous EBV-transformed B-cell lines labelled with 5lchromium, HLA-A2-matched, or HLA-A2-negative allogenic B-cell lines. Four hours after addition of clone ETMV1 with an effector-target ratio of 5:1, the supernatant was harvested and the specific lysis was calculated based on amount of chromium released. Addition of antibodies to CD8 showed that lysis is HLA class-I restricted.
The table shown in Fig. 4 indicates recognition of variant peptides by clone EB3. For this purpose, peptides at indicated concentrations were pre-incubated for one hour with autologous EBV-transformed B-cell lines labelled with 5lchromium. Five hours after addition of clone EB3 with an effector-target ratio of 8:1 or 10:1, the supernatant was harvested and specific lysis was calculated based on amount of chromium released. This clone recognizes non-mutated wild-type sequence of HIV, but not the sequence of this invention. It is shown that the sequence of this invention is a new CTL epitope.
SEQUENCE LISTING
<110> Glaxo Group Ltd.
Harrer Dr., Thomas <120> Medicaments for inducing cytotoxic T- cells <130> 77673m3 <140> PCT/EP99/02249 <141> 1999-04-O1 <150> DE 19814925.5 <151> 1998-04-03 <160> 42 <170> PatentIn Vers. 2.0 <210> 1 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 1 Ile Val Ile Tyr Gln Tyr Val Asp Asp Leu <210> 2 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 2 Ile Val Ile Cys Gln Tyr Val Asp Asp Leu <210> 3 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of fArtificial Sequence: Peptide <400> 3 Ile Val Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 4 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 4 Ile Val Ile Cys Gln Tyr Ile Asp Asp Leu <210> 5 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 5 Ile Thr Ile Tyr Gln Tyr Val Asp Asp Leu <210> 6 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 6 Ile Thr Ile Cys Gln Tyr Val Asp Asp Leu <210> 7 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 7 Ile Thr Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 8 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 8 Ile Thr Ile Cys Gln Tyr Ile Asp Asp Leu <210> 9 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 9 Ile Ile Ile Tyr Gln Tyr Val Asp Asp Leu <210> 10 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> to Ile Ile Ile Cys Gln Tyr Val Asp Asp Leu <210> 11 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 11 Ile Ile Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 12 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 12 Ile Ile Ile Cys Gln Tyr Ile Asp Asp Leu <210> 13 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 13 Met Val Ile Tyr Gln Tyr Val Asp Asp Leu <210> 14 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 14 Met Val Ile Cys Gln Tyr Val Asp Asp Leu 1 , 5 10 <210> 15 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 15 Met Val Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 16 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 16 Met Val Ile Cys Gln Tyr Ile Asp Asp Leu <210> 17 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 17 Val Ile Tyr Gln Tyr Val Asp Asp Leu <21D> 18 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> la Val Ile Cys Gln Tyr Val Asp Asp Leu <210> 19 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 19 Val Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 20 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 20 Val Ile Cys Gln Tyr Ile Asp Asp Leu <210> 21 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 21 Leu Ile Tyr Gln Tyr Val Asp Asp Leu <21D> 22 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 22 Leu Ile Cys Gln Tyr Val Asp Asp Leu <210> 23 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 23 Leu Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 24 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 24 Leu Ile Cys Gln Tyr Ile Asp Asp Leu <210> 25 <211> 11 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial 5equence:Peptide <400> 25 Thr Ile Leu Gln Tyr Val Asp Asp Ile Leu Leu <210> 26 <211> 11 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 26 Thr Ile Leu Gln Tyr Ile Asp Asp Ile Leu Leu <210> 27 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 27 Ile Leu Gln Tyr Val Asp Asp Ile Leu <210> 28 <211> 9 <212> P~RT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 28 Ile Leu Gln Tyr Ile Asp Asp Ile Leu <210> 29 <211> 11 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 29 Thr Ile Val Gln Tyr Val Asp Asp Ile Leu Leu <210> 30 <211> 11 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 30 Thr Ile Val Gln Tyr Ile Asp Asp Ile Leu Leu <210> 31 <211> 9 <212> PRT
<213> Artificial Sequence <220>
~
<223> Description of Artificial Sequence: Peptide <400> 31 Ile Val Gln Tyr Ile Asp Asp Ile Leu <210> 32 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 32 Ile Val Gln Tyr Ile Asp Asp Ile Leu <210> 33 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 33 Ile Leu Val Gln Tyr Val Asp Asp Ile Leu <210> 34 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 34 Ile Leu Val Gln Tyr Ile Asp Asp Ile Leu <210> 35 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 35 Ile Ile Ile Gln Tyr Val Asp Asp Ile Leu <210> 36 <211> 10 <212> PRT
<213> Artificial Sequence <22D>
<223> Description of Artificial Sequence: Peptide <400> 36 Ile Ile Ile Gln Tyr Ile Asp Asp Ile Leu <210> 37 <211> 10 <212> PRT
<213> Artificial Sequence <22D>
<223> Description of Artificial Sequence: Peptide <4DD> 37 Ile Leu Ile Gln Tyr Val Asp Asp Ile Leu <210> 38 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 38 Ile Leu Ile Gln Tyr Ile Asp Asp Ile Leu <210> 39 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 39 Val Leu Tyr Gln Tyr Val Asp Asp Leu <210> 40 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 40 Val Leu Cys Gln Tyr Va 1 Asp Asp Leu <210> 41 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 41 Val Leu Tyr Gln Tyr Ile Asp Asp Leu <210> 42 <211> 9 <212> PRT
<213> Artif_cial Sequence <220>
<223> Descr_ption of Artificial Sequence: Peptide <400> 42 Val Leu Cys Gln Tyr Ile Asp Asp Leu
For purposes of immunization, the amino acid sequence may be a component of a peptide or protein. The peptide or protein may be coupled to a lipopeptide or lipoprotein, preferably tripalmitoyl-S-glyceryl-cysteinyl-Beryl-serine. Depending on the purpose, the peptide or protein may be contained within a liposome or ISCOM (immunostimulatory complex). The peptide or protein may however also be coupled to a viral protein which preferably is selected from the following group: HIV virus-like particles, HIV gag particles, or HBs antigens.
This peptide may preferably be present as a peptide-HLA
complex in soluble form, e.g. as HLA-A2 tetramer. The above-mentioned complex may be bound to a liposome. The peptide may however also be part of a cell presenting an antigen, preferably a dendritic cell, macrophage, B cell, or CD4+ T
cell. This may be achieved both by exogenic addition of the peptide to the cell and endogenic processing of proteins expressed in the cell.
According to the invention, this medicament may further contain cytokines such as interleukin-2 and/or GM-CSF, or polyvalent vaccines. It has proven especially beneficial to select the amino acid sequence from among the following sequences:
IVIYQYVDDL(SEQ ID N0:1), IVICQYVDDL (SEQ ID N0:2), IVIYQYIDDL(SEQ ID N0:3), IVICQYIDDL (SEQ ID N0:4), ITIYQYVDDL(SEQ ID N0:5), ITICQYVDDL (SEQ ID N0:6), ITIYQYIDDL(SEQ ID N0:7), ITICQYIDDL (SEQ ID N0:8), IIIYQYVDDL(SEQ ID N0:9), IIICQYVDDL (SEQ ID NO:10) IIIYQYIDDL(SEQ ID N0:11), IIICQYIDDL (SEQ ID N0:12), MVIYQYVDDL(SEQ ID N0:13), MVICQYVDDL (SEQ ID N0:14), MVIYQYIDDL(SEQ ID N0:15), MVICQYIDDL (SEQ ID N0:16), VIYQYVDDL (SEQ ID N0:17), VICQYVDDL (SEQ ID N0:18), VIYQYIDDL (SEQ ID N0:19), VICQYIDDL (SEQ ID N0:20), LIYQYVDDL (SEQ ID N0:21), LICQYVDDL (SEQ ID N0:22), LIYQYIDDL (SEQ ID N0:23), LICQYIDDL (SEQ ID N0:24), TILQYVDDILL Q ID N0:25), TICQYVDDILL
(SE (SEQ ID
N0:26), ILQYVDDIL (SEQ ID N0:27), ILQYIDDIL (SEQ ID N0:28), TIVQYVDDILL TIVQYIDDILL
(SEQ ID (SEQ ID
N0:29), N0:30), IVQYIDDIL (SEQ ID N0:31), IVQYIDDIL (SEQ ID N0:32), ILVQYVDDIL(SEQ ID N0:33), ILVQYIDDIL (SEQ ID N0:34), IIIQYVDDIL(SEQ ID N0:35), IIIQYIDDIL (SEQ ID N0:36), ILIQYVDDIL(SEQ ID N0:37), ILIQYIDDIL (SEQ ID N0:38), VLYQYVDDL (SEQ ID N0:39), VLCQYVDDL (SEQ ID N0:40), VLYQYIDDL (SEQ ID N0:41), VLCQYIDDL (SEQ ID N0:42), where V = valine, I - isoleucine, L = leucine, M =
methionine, C = cysteine, and Q = glutamine. The nucleic acid sequence may be a DNA or RNA sequence. It is possible for the nucleic acid sequence to be a component of a plasmid or viral vector, preferably of a recombinant vaccinia virus or recombinant adenovirus, or a retroviral vector. The nucleic acid sequence may also be a component of retroviral vectors or attenuated retroviruses. Furthermore, the nucleic acid may be a component of a bacterial vector, preferably a recombinant BCG or salmonella vector or inactivated virus, preferably HIV virus. According to the invention, the medicament may also be used in the ex vivo production of T
cells or T cell receptors.
An additional object of the present invention is the use of a medicament according to the present invention for prevention or treatment of viral infection, preferably involving mutated HIV, HIV-1, HIV-2, HTLV-I, or HTLV-II viruses, or mutated hepatitis B viruses. The viruses may also be mutated viruses resistant to (-)-2',3'-dideoxy-3'-thiacytidine [3TC
(lamivudine)], (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purine-9-yl]-2-cyclopentene-1-methanol [abacavir], 2',3'-dideoxyinosine [didanosin], 2',3'-dideoxycytidine [zalcitabin], (-)-2'-deoxy-5-fluoro-3'-thiacytidine [FTC].
The efficacy of the medicament of this invention is, for example, explained using a graphic representation of experimental results. The following is shown here:
Fig. 1 recognition of CTL epitope VIYQYVDDL (SEQ ID N0:17) or VIYQYIDDL (SEQ ID N0:19) by CTL clone ETMV1 and non-recognition of CTL epitope VIYQYMDDL described above by the same clone, Fig. 2 specific lysis of clone of ETMV1 during titration of peptides VIYQYVDDL (SEQ ID N0:17) and VIYQYIDDL
(SEQ ID N0:19), Fig. 3 recognition of peptide VIYQYVDDL (SEQ ID N0:17), and Fig. 4 non-recognition of peptides VIYQYVDDL (SEQ ID
N0:17) and VIYQYIDDL (SEQ ID N0:19) by CTL clone EB3, which recognizes the wild-type sequence VIYQYMDDL.
In Fig. 1, the peptides were pre-incubated at a concentration of 1 ~Cg/ml for one hour with autologous EBV transformed B-cell lines labelled with 5lchromium. Four hours after addition of clone ETMVl with an effector-target ratio of 15:1, the supernatant was harvested and the specific lysis was calculated based on the amount of chromium released. The p17-peptide KIRLRPGGK was used as control. As can be inferred from Fig. 1, only peptides IVIYQYVDDL (SEQ ID NO:1), VIYQYVDDL (SEQ ID N0:17), and VIYQYIDDL (SEQ ID N0:19) were recognized, which contain resistance mutations against reverse transcriptase inhibitors. Wild-type peptide VIYQYMDDL was not recognized.
In order to achieve the results represented in Fig. 2, the peptides described therein were pre-incubated for one hour at concentrations as indicated with autologous EBV-transformed B-cell lines labelled with 5lchromium. Four hours after addition of clone ETMV1 with an effector-target ratio of 5:1, the supernatant was harvested and the specific lysis was calculated based on amounts of chromium released.
Fig. 3 indicates recognition of peptide VIYQYVDDL (SEQ ID
N0:17) (=RT50 M/V). It is HLA-A2 restricted. The shown results were achieved by pre-incubating the peptide and control peptide for one hour at a concentration of 10 ug/ml with autologous EBV-transformed B-cell lines labelled with 5lchromium, HLA-A2-matched, or HLA-A2-negative allogenic B-cell lines. Four hours after addition of clone ETMV1 with an effector-target ratio of 5:1, the supernatant was harvested and the specific lysis was calculated based on amount of chromium released. Addition of antibodies to CD8 showed that lysis is HLA class-I restricted.
The table shown in Fig. 4 indicates recognition of variant peptides by clone EB3. For this purpose, peptides at indicated concentrations were pre-incubated for one hour with autologous EBV-transformed B-cell lines labelled with 5lchromium. Five hours after addition of clone EB3 with an effector-target ratio of 8:1 or 10:1, the supernatant was harvested and specific lysis was calculated based on amount of chromium released. This clone recognizes non-mutated wild-type sequence of HIV, but not the sequence of this invention. It is shown that the sequence of this invention is a new CTL epitope.
SEQUENCE LISTING
<110> Glaxo Group Ltd.
Harrer Dr., Thomas <120> Medicaments for inducing cytotoxic T- cells <130> 77673m3 <140> PCT/EP99/02249 <141> 1999-04-O1 <150> DE 19814925.5 <151> 1998-04-03 <160> 42 <170> PatentIn Vers. 2.0 <210> 1 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 1 Ile Val Ile Tyr Gln Tyr Val Asp Asp Leu <210> 2 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 2 Ile Val Ile Cys Gln Tyr Val Asp Asp Leu <210> 3 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of fArtificial Sequence: Peptide <400> 3 Ile Val Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 4 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 4 Ile Val Ile Cys Gln Tyr Ile Asp Asp Leu <210> 5 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 5 Ile Thr Ile Tyr Gln Tyr Val Asp Asp Leu <210> 6 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 6 Ile Thr Ile Cys Gln Tyr Val Asp Asp Leu <210> 7 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 7 Ile Thr Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 8 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 8 Ile Thr Ile Cys Gln Tyr Ile Asp Asp Leu <210> 9 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 9 Ile Ile Ile Tyr Gln Tyr Val Asp Asp Leu <210> 10 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> to Ile Ile Ile Cys Gln Tyr Val Asp Asp Leu <210> 11 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 11 Ile Ile Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 12 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 12 Ile Ile Ile Cys Gln Tyr Ile Asp Asp Leu <210> 13 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 13 Met Val Ile Tyr Gln Tyr Val Asp Asp Leu <210> 14 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 14 Met Val Ile Cys Gln Tyr Val Asp Asp Leu 1 , 5 10 <210> 15 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 15 Met Val Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 16 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 16 Met Val Ile Cys Gln Tyr Ile Asp Asp Leu <210> 17 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 17 Val Ile Tyr Gln Tyr Val Asp Asp Leu <21D> 18 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> la Val Ile Cys Gln Tyr Val Asp Asp Leu <210> 19 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 19 Val Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 20 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 20 Val Ile Cys Gln Tyr Ile Asp Asp Leu <210> 21 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 21 Leu Ile Tyr Gln Tyr Val Asp Asp Leu <21D> 22 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 22 Leu Ile Cys Gln Tyr Val Asp Asp Leu <210> 23 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 23 Leu Ile Tyr Gln Tyr Ile Asp Asp Leu <210> 24 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 24 Leu Ile Cys Gln Tyr Ile Asp Asp Leu <210> 25 <211> 11 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial 5equence:Peptide <400> 25 Thr Ile Leu Gln Tyr Val Asp Asp Ile Leu Leu <210> 26 <211> 11 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 26 Thr Ile Leu Gln Tyr Ile Asp Asp Ile Leu Leu <210> 27 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 27 Ile Leu Gln Tyr Val Asp Asp Ile Leu <210> 28 <211> 9 <212> P~RT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 28 Ile Leu Gln Tyr Ile Asp Asp Ile Leu <210> 29 <211> 11 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 29 Thr Ile Val Gln Tyr Val Asp Asp Ile Leu Leu <210> 30 <211> 11 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 30 Thr Ile Val Gln Tyr Ile Asp Asp Ile Leu Leu <210> 31 <211> 9 <212> PRT
<213> Artificial Sequence <220>
~
<223> Description of Artificial Sequence: Peptide <400> 31 Ile Val Gln Tyr Ile Asp Asp Ile Leu <210> 32 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 32 Ile Val Gln Tyr Ile Asp Asp Ile Leu <210> 33 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 33 Ile Leu Val Gln Tyr Val Asp Asp Ile Leu <210> 34 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 34 Ile Leu Val Gln Tyr Ile Asp Asp Ile Leu <210> 35 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 35 Ile Ile Ile Gln Tyr Val Asp Asp Ile Leu <210> 36 <211> 10 <212> PRT
<213> Artificial Sequence <22D>
<223> Description of Artificial Sequence: Peptide <400> 36 Ile Ile Ile Gln Tyr Ile Asp Asp Ile Leu <210> 37 <211> 10 <212> PRT
<213> Artificial Sequence <22D>
<223> Description of Artificial Sequence: Peptide <4DD> 37 Ile Leu Ile Gln Tyr Val Asp Asp Ile Leu <210> 38 <211> 10 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 38 Ile Leu Ile Gln Tyr Ile Asp Asp Ile Leu <210> 39 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 39 Val Leu Tyr Gln Tyr Val Asp Asp Leu <210> 40 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 40 Val Leu Cys Gln Tyr Va 1 Asp Asp Leu <210> 41 <211> 9 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Peptide <400> 41 Val Leu Tyr Gln Tyr Ile Asp Asp Leu <210> 42 <211> 9 <212> PRT
<213> Artif_cial Sequence <220>
<223> Descr_ption of Artificial Sequence: Peptide <400> 42 Val Leu Cys Gln Tyr Ile Asp Asp Leu
Claims (29)
1. A compound containing or consisting of an amino acid or nucleic acid encoding said amino acid, wherein said amino acid has the following sequence:
X1-Y-X2-D-D-X3, wherein Xl - at least one of any amino acid Y - tyrosine X2 = one amino acid selected from the following group:
valine, isoleucine, and leucine D = aspartate, and X3 = at least one of any additional amino acid, except for the following amino acid sequences:
LRVEYLDDR, TLVLQYVDDLLL, and ILVLQYVDDLLL, with T = threonine, V = valine, I = isoleucine, L = leucine, Q = glutamine, and R = arginine.
X1-Y-X2-D-D-X3, wherein Xl - at least one of any amino acid Y - tyrosine X2 = one amino acid selected from the following group:
valine, isoleucine, and leucine D = aspartate, and X3 = at least one of any additional amino acid, except for the following amino acid sequences:
LRVEYLDDR, TLVLQYVDDLLL, and ILVLQYVDDLLL, with T = threonine, V = valine, I = isoleucine, L = leucine, Q = glutamine, and R = arginine.
2. A compound according to claim 1, wherein said amino acid sequence consists of nine amino acids.
3. A compound according to any one of the preceding claims, wherein X1 is a sequence consisting of four or five amino acids.
4. A compound according to any one of the preceding claims, wherein X3 is a sequence consisting of one or two additional amino acids.
5. A compound according to any one of the preceding claims, wherein said amino acid sequence is a component of a peptide.
6. A compouna according to any one of the preceding claims, wherein said amino acid sequence is a component of a protein.
7. A compound according to any one of the preceding claims, wherein said peptide or protein is coupled to a lipopeptide or lipoprotein, preferably to tripalmitoyl-S-glycerylcysteinyl-seryl-serine.
8. A compound according to any one of the preceding claims, wherein said peptide or protein is contained within a liposome or ISCOM.
9. A compound according to any one of the preceding claims, wherein said peptide or protein is coupled to a viral protein.
10. A compound according to any one of the preceding claims, wherein said peptide is selected from the following group: HIV virus-like particles, HIV gag-particles, or HBs antigens.
11. A compound according to any one of the preceding claims, wherein said peptide is present as a soluble peptide-HLA
complex, preferably as a HLA-A2 tetramer.
complex, preferably as a HLA-A2 tetramer.
12. A compound according to any one of the preceding claims, wherein said peptide is present as a soluble peptide-HLA
complex bound to a liposome.
complex bound to a liposome.
13. A compound according to any one of the preceding claims, wherein said peptide is a component of an antigen-presenting cell, preferably dendritic cell, macrophage, B cell or CD4+ T cell.
14. A compound according to any one of the preceding claims, wherein said amino acid sequence is selected from among the following amino acid sequences:
IVIYQYVDDL (SEQ ID NO:1), IVICQYVDDL (SEQ ID NO:2), IVIYQYIDDL (SEQ ID NO:3), IVICQYIDDL (SEQ ID NO:4), ITIYQYVDDL (SEQ ID NO:5), ITICQYVDDL (SEQ ID NO:6), ITIYQYIDDL (SEQ ID NO:7), ITICQYIDDL (SEQ ID NO:8), IIIYQYVDDL (SEQ ID NO:9), IIICQYVDDL (SEQ ID NO:10) IIIYQYIDDL (SEQ ID NO:11), IIICQYIDDL (SEQ ID NO:12), MVIYQYVDDL (SEQ ID NO:13), MVICQYVDDL (SEQ ID NO:14), MVIYQYIDDL (SEQ ID NO:15), MVICQYIDDL (SEQ ID NO:16), VIYQYVDDL (SEQ ID NO:17), VICQYVDDL (SEQ ID NO:18), VIYQYIDDL (SEQ ID NO:19), VICQYVDDL (SEQ ID NO:20), LIYQYVDDL (SEQ ID NO:21), LICQYVDDL (SEQ ID NO:22), LIYQYIDDL (SEQ ID NO:23), LICQYIDDL (SEQ ID NO:24), TILQYVDDILL (SEQ ID NO:25), TICQYVDDILL (SEQ ID NO:26), ILQYVDDIL (SEQ ID NO:27), ILQYIDDIL (SEQ ID NO:28), TIVQYVDDILL (SEQ ID NO:29), TIVQYIDDILL (SEQ ID NO:30), IVQYIDDIL (SEQ ID NO:31), IVQYIDDIL (SEQ ID NO:32), ILVQYVDDIL (SEQ ID NO:33), ILVQYIDDIL (SEQ ID NO:34), IIIQYVDDIL (SEQ ID NO:35), IIIQYIDDIL (SEQ ID NO:36), ILIQYVDDIL (SEQ ID NO:37), ILIQYIDDIL (SEQ ID NO:38), VLYQYVDDL (SEQ ID NO:39), VLCQYVDDL (SEQ ID NO:40), VLYQYIDDL (SEQ ID NO:41), VLCQYIDDL (SEQ ID NO:42), where C = cysteine, D = aspartate, I = isoleucine, L =
leucine, M = methionine, and Q = glutamine.
IVIYQYVDDL (SEQ ID NO:1), IVICQYVDDL (SEQ ID NO:2), IVIYQYIDDL (SEQ ID NO:3), IVICQYIDDL (SEQ ID NO:4), ITIYQYVDDL (SEQ ID NO:5), ITICQYVDDL (SEQ ID NO:6), ITIYQYIDDL (SEQ ID NO:7), ITICQYIDDL (SEQ ID NO:8), IIIYQYVDDL (SEQ ID NO:9), IIICQYVDDL (SEQ ID NO:10) IIIYQYIDDL (SEQ ID NO:11), IIICQYIDDL (SEQ ID NO:12), MVIYQYVDDL (SEQ ID NO:13), MVICQYVDDL (SEQ ID NO:14), MVIYQYIDDL (SEQ ID NO:15), MVICQYIDDL (SEQ ID NO:16), VIYQYVDDL (SEQ ID NO:17), VICQYVDDL (SEQ ID NO:18), VIYQYIDDL (SEQ ID NO:19), VICQYVDDL (SEQ ID NO:20), LIYQYVDDL (SEQ ID NO:21), LICQYVDDL (SEQ ID NO:22), LIYQYIDDL (SEQ ID NO:23), LICQYIDDL (SEQ ID NO:24), TILQYVDDILL (SEQ ID NO:25), TICQYVDDILL (SEQ ID NO:26), ILQYVDDIL (SEQ ID NO:27), ILQYIDDIL (SEQ ID NO:28), TIVQYVDDILL (SEQ ID NO:29), TIVQYIDDILL (SEQ ID NO:30), IVQYIDDIL (SEQ ID NO:31), IVQYIDDIL (SEQ ID NO:32), ILVQYVDDIL (SEQ ID NO:33), ILVQYIDDIL (SEQ ID NO:34), IIIQYVDDIL (SEQ ID NO:35), IIIQYIDDIL (SEQ ID NO:36), ILIQYVDDIL (SEQ ID NO:37), ILIQYIDDIL (SEQ ID NO:38), VLYQYVDDL (SEQ ID NO:39), VLCQYVDDL (SEQ ID NO:40), VLYQYIDDL (SEQ ID NO:41), VLCQYIDDL (SEQ ID NO:42), where C = cysteine, D = aspartate, I = isoleucine, L =
leucine, M = methionine, and Q = glutamine.
15. A compound according to any one of the preceding claims, wherein said nucleic acid sequence is a DNA or RNA
sequence.
sequence.
16. A compound according to any one of the preceding claims, wherein said nucleic acid sequence is a component of a plasmid or viral vector, preferably a recombinant vaccinia virus, adenovirus, or retroviral vector.
17. A compound according to any one of the preceding claims, wherein said nucleic acid sequence is a component of a bacterial vector, preferably of a recombinant BCG or salmonella vector.
18. A compound according to any one of the preceding claims, wherein said nucleic acid sequence is a component of an inactivated virus, preferably an inactivated HIV virus.
19. A medicament containing as active ingredient a compound according to any one of the preceding claims.
20. A medicament according to claim 19 in form of a vaccine.
21. A medicament according to claim 20 containing polyvalent vaccines.
22. A medicament according to any one of claims 19 through 21, wherein one or more cytokines are contained as adjuvant.
23. A medicament according to any one of claims 19 through 22, wherein interleukin-2 and/or GM-CSF are contained as adjuvant.
24. A method for the prevention or treatment of infections with viruses, preferably mutated HIV, HIV-l, HIV-2, HTLV-I, and HTLV-II viruses or mutated hepatitis B
viruses or a disease responding to induction of cytotoxic T cells, consisting of administering to patient an effective dose of a medicament comprising a peptide of the following sequence:
X1-Y-X2-D-D-X3, wherein X1 = at least one of any amino acid Y = tyrosine, X2 = one amino acid selected from the following group:
valine (V), isoleucine (I), and leucine (L), D = aspartate, and X3 = at least one additional of any amino acid, or a nucleic acid encoding said peptide.
viruses or a disease responding to induction of cytotoxic T cells, consisting of administering to patient an effective dose of a medicament comprising a peptide of the following sequence:
X1-Y-X2-D-D-X3, wherein X1 = at least one of any amino acid Y = tyrosine, X2 = one amino acid selected from the following group:
valine (V), isoleucine (I), and leucine (L), D = aspartate, and X3 = at least one additional of any amino acid, or a nucleic acid encoding said peptide.
25. A method according to claim 24, wherein said mutant viruses are resistant to reverse transcriptase inhibitors.
26. A method according to claim 24 or 25, wherein said mutant viruses are resistant to (-)-2',3'-dideoxy-3'-thiacytidine [=3TC (lamivudine)] , (-)-(1S,4R) -4- [2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol [abacavir], 2',3'-dideoxyinosine [didanosin], 2',3'-dideoxycytidine [zalcitabin], (-)-2'-deoxy-5-fluoro-3'-thiacytidine [=FTC].
27. A use of the following amino acid sequence:
X1-Y-X2-D-D-X3, wherein X1 = at least one of any amino acid Y = tyrosine (T), X2 = one amino acid selected from the following group:
valine (V), isoleucine (I), and leucine (L), D = aspartate, and X3 = at least one of any additional amino acid, or a nucleic acid encoding said peptide, for the preparation of a medicament for the prevention or treatment of infections with viruses, preferably mutated HIV, HIV-1, HIV-2, HTLV-I, and HTLV-II viruses or mutated hepatitis B viruses or a disease responding to induction of cytotoxic T cells.
X1-Y-X2-D-D-X3, wherein X1 = at least one of any amino acid Y = tyrosine (T), X2 = one amino acid selected from the following group:
valine (V), isoleucine (I), and leucine (L), D = aspartate, and X3 = at least one of any additional amino acid, or a nucleic acid encoding said peptide, for the preparation of a medicament for the prevention or treatment of infections with viruses, preferably mutated HIV, HIV-1, HIV-2, HTLV-I, and HTLV-II viruses or mutated hepatitis B viruses or a disease responding to induction of cytotoxic T cells.
28. A use according to claim 27, wherein said mutant viruses are resistant to reverse transcriptase inhibitors.
29. A use according to claim 27 or claim 28, wherein said mutant viruses are resistant to (-)-2',3'-dideoxy-3'-thiacytidine [=3TC (lamivudine)], (-)-(1S, 4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (abacavir], 2',3'-dideoxyinosine [didanosin], 2',3'-dideoxycytidine [zalcitabin], (-)-2'-deoxy-5-fluoro-3'-thiacytidine [=FTC].
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19814925A DE19814925C2 (en) | 1998-04-03 | 1998-04-03 | Medicinal products for induction of cytotoxic T cells |
DE19814925.5 | 1998-04-03 | ||
PCT/EP1999/002249 WO1999051750A1 (en) | 1998-04-03 | 1999-04-01 | Medicaments for inducing cytotoxic t-cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2325345A1 CA2325345A1 (en) | 1999-10-14 |
CA2325345C true CA2325345C (en) | 2010-06-29 |
Family
ID=7863458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2325345A Expired - Fee Related CA2325345C (en) | 1998-04-03 | 1999-04-01 | Medicaments for inducing cytotoxic t-cells |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1068331B1 (en) |
JP (1) | JP2002510496A (en) |
KR (1) | KR20010042400A (en) |
AT (1) | ATE346935T1 (en) |
AU (1) | AU3704299A (en) |
BR (1) | BR9909389A (en) |
CA (1) | CA2325345C (en) |
DE (2) | DE19814925C2 (en) |
WO (1) | WO1999051750A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004092201A2 (en) * | 2003-03-31 | 2004-10-28 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced hiv-1 vaccines and methods for their use |
JP4779067B2 (en) * | 2004-01-20 | 2011-09-21 | 愛知県 | Epitope peptide recognized by HLA-A2402-restricted Ep-CAM specific CTL and use thereof |
WO2006091798A2 (en) * | 2005-02-22 | 2006-08-31 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus |
CN102438649A (en) * | 2009-03-24 | 2012-05-02 | 诺华有限公司 | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
WO2010109323A1 (en) * | 2009-03-24 | 2010-09-30 | Novartis Ag | Adjuvanting meningococcal factor h binding protein |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028871A1 (en) * | 1993-06-07 | 1994-12-22 | Endocon, Inc. | Implant stimulated cellular immunity |
CA2235168A1 (en) * | 1995-10-20 | 1997-04-24 | Duke University | Synthetic vaccine for protection against human immunodeficiency virus infection |
DE69739544D1 (en) * | 1996-11-26 | 2009-10-01 | Bio Merieux | VIRAL MATERIALS AND MULTIPLE SCLEROSIS ASSOCIATED NUCLEOTIDE FRAGMENTS WITH DIAGNOSTIC, PROPHYLACTIC AND THERAPEUTIC USES |
-
1998
- 1998-04-03 DE DE19814925A patent/DE19814925C2/en not_active Expired - Fee Related
-
1999
- 1999-04-01 WO PCT/EP1999/002249 patent/WO1999051750A1/en active Search and Examination
- 1999-04-01 AU AU37042/99A patent/AU3704299A/en not_active Abandoned
- 1999-04-01 DE DE59914027T patent/DE59914027D1/en not_active Expired - Fee Related
- 1999-04-01 AT AT99919176T patent/ATE346935T1/en not_active IP Right Cessation
- 1999-04-01 KR KR1020007010972A patent/KR20010042400A/en not_active Application Discontinuation
- 1999-04-01 BR BR9909389-8A patent/BR9909389A/en not_active IP Right Cessation
- 1999-04-01 JP JP2000542462A patent/JP2002510496A/en active Pending
- 1999-04-01 EP EP99919176A patent/EP1068331B1/en not_active Expired - Lifetime
- 1999-04-01 CA CA2325345A patent/CA2325345C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE19814925A1 (en) | 1999-10-07 |
EP1068331A1 (en) | 2001-01-17 |
BR9909389A (en) | 2000-12-05 |
ATE346935T1 (en) | 2006-12-15 |
DE59914027D1 (en) | 2007-01-11 |
JP2002510496A (en) | 2002-04-09 |
KR20010042400A (en) | 2001-05-25 |
WO1999051750A1 (en) | 1999-10-14 |
EP1068331B1 (en) | 2006-11-29 |
AU3704299A (en) | 1999-10-25 |
DE19814925C2 (en) | 2000-10-05 |
CA2325345A1 (en) | 1999-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100554487B1 (en) | Fusion proteins comprising hiv-1 tat and/or nef proteins | |
SG194360A1 (en) | Novel method and compositions | |
JP2011074081A (en) | Hiv peptide, antigen, vaccine composition, immunoassay kit, and method for detecting antibody induced by hiv | |
JP2004508381A (en) | HIV peptides, antigens, vaccine compositions, immunoassay kits and methods for detecting HIV-induced antibodies | |
KR20140131929A (en) | Polynucleotides for treating oncogenic viral polypeptide positive tumors | |
EP2892554B1 (en) | Hiv immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto | |
AU2015292261A1 (en) | Constrained proteins and uses therefor | |
JP6863966B2 (en) | Polypeptide Carriers and Their Use to Present Target Polypeptides | |
Döşkaya et al. | GRA1 protein vaccine confers better immune response compared to codon-optimized GRA1 DNA vaccine | |
CA2304125A1 (en) | Attenuated vif dna immunization cassettes for genetic vaccines | |
CA2325345C (en) | Medicaments for inducing cytotoxic t-cells | |
KR20080098585A (en) | Treatment of epstein-barr virus-associated diseases | |
US20090028932A1 (en) | Vaccine formulations for leishmania | |
CA2469487A1 (en) | Mutated hiv tat | |
EP0563323A1 (en) | Hiv reverse transcriptase vaccine | |
CA2803029A1 (en) | Constrained immunogenic compositions and uses therefor | |
JP2012509906A (en) | Peptide adjuvant | |
KR20140116091A (en) | Mutated lentiviral env proteins and their use as drugs | |
US20080089929A1 (en) | Fusion proteins comprising hiv-1 tat and/or nef proteins | |
RU2731073C1 (en) | Herpes vaccine | |
CN113957097B (en) | Immunogen for broad-spectrum neutralization protection of novel crown variant strain and preparation method and application thereof | |
US20060051360A1 (en) | Tat as an immunogen | |
CN116789844A (en) | Chimeric antigen receptor of targeted CD7 protein and application thereof | |
CN116490204A (en) | Catalytic inactivation of angiotensin converting enzyme 2 (ACE 2) variants and uses thereof | |
O'Hagan et al. | Gillis Otten, Mary Schaefer, Catherine Greer, Maria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20170403 |